We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Recall-Prompting Labeling Bungle Spurs Takeda Review of CMO Oversight
Recall-Prompting Labeling Bungle Spurs Takeda Review of CMO Oversight
February 13, 2013
Takeda plans to reexamine its supplier oversight practices after a contract manufacturer it owns bungled the labeling for a vitamin B1 deficiency drug, prompting regulatory penalties in Japan.